Zenkuda's 6-Month Dosing Claim Is the Bet — Safety Data Will Decide the Payoff

Zenkuda and Tabirafusp-ted Achieve Primary Endpoints in DAYBREAK wAMD Trial

Kodiak Sciences announced that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) met their primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration (wAMD). Zenkuda demonstrated non-inferiority in vision gains compared to aflibercept at year one, showing rapid and sustained retinal drying. A significant 54% of Zenkuda patients achieved a 6-month dosing durability at year one using strict treat-to-dryness criteria. Kodiak plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in Q4 2026, based on five positive Phase 3 studies across wAMD, diabetic retinopathy, and retinal vein occlusion. Tabirafusp-ted also met its vision and anatomical endpoints, with further development planned for diabetic macular edema in the ALTO study. Both drugs showed safety consistent with aflibercept.

• Zenkuda (tarcocimab tedromer) achieved non-inferiority in vision gains compared to aflibercept at year one in the DAYBREAK study for wAMD. It demonstrated strong immediacy of clinical effect, matching or exceeding aflibercept during the loading phase, and notable durability, with 54% of patients maintaining a 6-month dosing interval at year one under strict treat-to-dryness retreatment criteria. The drug also showed a favorable safety profile with 0% intraocular inflammation and 0.5% cataract adverse event rate.
• Kodiak Sciences plans a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026. This submission will be supported by data from five successful Phase 3 studies: DAYBREAK and DAYLIGHT in wAMD, GLOW and GLOW2 in diabetic retinopathy (DR), and BEACON in macular edema following retinal vein occlusion (RVO), positioning Zenkuda as a potential best-in-class therapy across major retinal vascular diseases.
• Tabirafusp-ted (KSI-501) also met its vision primary endpoint (p-value of 0.0036) and anatomical key secondary endpoint (p-value of <0.0001) in the DAYBREAK study. While post-hoc analyses are planned for wAMD subgroups, Kodiak is accelerating its development program for tabirafusp-ted in diabetic macular edema (DME) and is actively enrolling patients in the Phase 3 ALTO study, exploring its potential superiority as a bispecific anti-VEGF, anti-IL-6 therapy.

Zenkuda's DAYBREAK Results: Efficacy and Durability in Wet AMD

Recent clinical investigations into neovascular AMD have highlighted meaningful advances in both novel agents and treatment paradigms. A 2026 retrospective observational study comparing aflibercept 8 mg and faricimab during the loading phase enrolled 100 treatment-naïve eyes receiving three consecutive monthly injections of either agent. In the aflibercept 8 mg group, mean BCVA improved from 0.59±0.51 logMAR to 0.39±0.44 logMAR at 3 months (P<0.001), with mean CRT decreasing from 450.6±157.0 µm to 287.3±82.3 µm (P<0.001). In the faricimab group, mean BCVA improved from 0.62±0.47 logMAR to 0.45±0.38 logMAR (P<0.001), with CRT decreasing from 442.4±163.8 µm to 248.5±81.2 µm (P<0.001). Complete retinal fluid resolution was achieved in 80.4% and 87.8% of patients in the aflibercept 8 mg and faricimab groups, respectively, with no statistically significant differences between groups in BCVA improvement (P=0.685), CRT reduction (P=0.320), or fluid resolution (P=0.234).

A separate 2026 retrospective chart review examined 159 patients with neovascular AMD refractory to aflibercept 2 mg who were switched to either aflibercept 8 mg (n=78) or faricimab (n=81). Over six months, mean BCVA and CRT did not differ significantly between groups. However, at month 6, the faricimab group demonstrated significant reductions in CRT, subfoveal choroidal thickness, Haller layer thickness, and maximum PED height, whereas the aflibercept 8 mg group did not show significant changes in these parameters. Choroidal vascularity index increased significantly after switching to faricimab, with no significant change observed in the aflibercept 8 mg group. A lower proportion of eyes with IRF and/or SRF was also observed in the faricimab group at month 6, suggesting faricimab may confer additional anatomical benefits — particularly in choroidal structural parameters — in aflibercept 2 mg-resistant disease.

A 2026 systematic review and network meta-analysis evaluating different aflibercept regimens for wet AMD included seven randomized controlled trials encompassing 1,683 patients. No significant interregimen differences were observed in visual acuity or central retinal thickness across bimonthly, monthly, treat-and-extend (TAE), and pro re nata (PRN) regimens. The TAE regimen required significantly fewer injections than bimonthly dosing (SMD -1.091, 95% CI -2.030 to -0.153) and monthly dosing (SMD -3.024, 95% CI -4.584 to -1.465), as did the PRN regimen versus bimonthly (SMD -1.919, 95% CI -3.307 to -0.532) and monthly dosing (SMD -3.852, 95% CI -5.717 to -1.988). Injection counts did not differ significantly between TAE and PRN (SMD 0.828, 95% CI -0.847 to 2.503); however, the TAE regimen was associated with fewer clinic visits than PRN, supporting its utility in reducing overall treatment burden while maintaining efficacy.

Zenkuda's Broad Potential Across Retinal Vascular Diseases

Beyond neovascular age-related macular degeneration, KSI-301 (the antibody-biopolymer conjugate also referred to in the query as tarcocimab tedromer / Zenkuda) is being investigated in clinical trials for diabetic retinopathy (DR), diabetic macular edema (DME), and retinal vein occlusion (RVO).

• Diabetic Macular Edema (DME): KSI-301 is identified as a potential future intravitreal anti-VEGF agent for DME, with phase 3 trials ongoing to evaluate its efficacy, duration, and safety in this indication.

• Diabetic Retinopathy (DR): KSI-301 is under investigation for DR more broadly, with clinical research aimed at demonstrating higher target-protein binding affinity and prolonged therapeutic effect relative to currently approved agents.

• Retinal Vein Occlusion (RVO): Phase 3 trials are ongoing for RVO, alongside those for nAMD and DME, to further characterise KSI-301's clinical profile in this indication.

The knowledge base does not have sufficient information on this aspect regarding the specific intervention models (e.g., parallel assignment, crossover) for each of these trials.

Tabirafusp-ted: A Bispecific Strategy for Retinal Diseases

Beyond anti-VEGF monotherapy, research into wet AMD has expanded to encompass several distinct molecular targets. The angiopoietin (ANGPT)/Tie2 axis has attracted considerable attention: Tie2 phosphorylation by ANGPT1 is associated with vascular stability, while ANGPT2 potentiates angiogenesis. The bispecific ANGPT2/VEGF-blocking antibody faricimab has been approved for neovascular AMD and has demonstrated meaningful clinical activity in resistant choroidal neovascularization (CNV), including reductions in vessel area, total vessel length, total number of junctions, central retinal thickness (CRT) by 9.94%, pigment epithelial detachment (PED) volume by 20.94%, and total retinal fluid by 84.06%, alongside an increased mean injection interval of 3.19 ± 2.47 weeks. In treatment-naïve patients, faricimab reduced CRT from 433.6 µm at baseline to 241.5 µm at three months (p < 0.0001), with IRF and SRF volumes reduced by >99% and BCVA improving from 0.60 to 0.40 logMAR (p < 0.0001). Investigational Tie2 activation via Hepta-ANGPT1 — an ANGPT1-mimetic fusion protein with improved activity, solubility, and half-life — has, however, revealed context-dependent complexity: while it induced robust Tie2 phosphorylation in the choroid without causing angiogenesis in healthy eyes, it potentiated neovascularization in laser-induced and RNV3 CNV models, underscoring that Tie2 activation can be detrimental under certain pathological conditions.

Platelet-derived growth factor (PDGF) signaling represents a complementary target, given its pivotal role in pericyte-induced stabilization of CNV and its contribution to partial anti-VEGF resistance. Axitinib, a tyrosine kinase inhibitor that interferes with both VEGFR and PDGFR signaling and is approved for renal cell carcinoma, has demonstrated anti-angiogenic properties in vitro: it significantly inhibited proliferation in human endothelial cells (HUVEC) and human pericytes in a dose-dependent manner, normalized VEGF- and PDGF-stimulated cellular migration, and significantly reverted VEGF-induced capillary structure formation — all at non-toxic concentrations. Integrin signaling constitutes another emerging avenue; THR-687, a novel pan-RGD integrin receptor antagonist, competes for binding with nanomolar potency (e.g., IC₅₀ of 4.4 ± 2.7 nM for αvβ3, 1.3 ± 0.5 nM for αvβ6, and 6.8 ± 3.2 nM for αvβ8), prevented HUVEC migration (IC₅₀ of 258 ± 113 nM) and vessel sprouting in an ex vivo mouse choroidal explant model (IC₅₀ of 236 ± 173 nM), induced regression of pre-existing vascular sprouts, and potently inhibited neovascularization-induced leakage in a cynomolgus laser-induced CNV model at intravitreal doses of 0.45 mg, 2.25 mg, and 4.5 mg/eye.

Gene therapy approaches are also advancing as a strategy to achieve sustained target suppression and reduce injection burden. Intravitreal delivery of rAAV2-sVEGFRv-1 — a recombinant adeno-associated virus 2 expressing a soluble variant of VEGF receptor-1 — significantly decreased CNV lesion size (1336 ± 186) compared to rAAV2-GFP-treated (2949 ± 437, P = 0.0043) and mock-treated models (3075 ± 265, P = 0.0013), while also reducing inflammatory cell infiltration and demonstrating antiapoptotic activity. Current clinical-stage gene therapy programs in wet AMD include ADVM-022 and RGX-314. More broadly, emerging therapeutic strategies encompass PDGF, angiopoietin-2, Tie2, and integrin inhibitors, alongside long-acting biologics, nanocarriers, and complementary approaches targeting inflammation, hypoxia, and neuroprotection — collectively aimed at overcoming anti-VEGF resistance and preserving retinal function.

Extended Durability: A New Horizon for Retinal Disease Management

The landscape of retinal disease management is on the cusp of a significant transformation, driven by the imperative to alleviate the substantial burden associated with frequent intravitreal injections. For patients grappling with chronic conditions like wet age-related macular degeneration (wAMD), diabetic retinopathy, and retinal vein occlusion, the prospect of fewer clinic visits and less frequent injections is a profound improvement in quality of life. Research consistently highlights the limitations of current anti-VEGF therapies in terms of treatment burden and incomplete responses, spurring the development of innovative strategies.

Zenkuda (tarcocimab tedromer) emerges as a strong candidate to address this unmet need. Its demonstrated non-inferiority to existing gold-standard treatments in vision gains, coupled with a remarkable 54% of patients achieving a 6-month dosing durability under strict treat-to-dryness criteria, represents a tangible step towards extended treatment intervals. This durability is not merely a convenience; it is a critical factor in improving patient adherence and optimizing healthcare resource utilization. The strategic decision to pursue a multi-indication Biologics License Application for Zenkuda further underscores its potential to become a cornerstone therapy across several major retinal diseases.

Beyond Zenkuda, the positive results for tabirafusp-ted (KSI-501) signal an exciting evolution in therapeutic approaches. As a multitargeted biologic, KSI-501's success validates a shift towards mechanistically diverse strategies that combine anti-angiogenic and anti-inflammatory effects. This move beyond purely anti-VEGF pathways reflects a broader industry trend towards more comprehensive vascular stabilization and neuroprotection, offering the potential for improved outcomes in patients who may not fully respond to current treatments. However, as with all emerging therapies, long-term safety, efficacy, and durability data will be paramount in determining which of these candidates ultimately redefine the standard of care and achieve widespread clinical adoption.